Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dissolvable magnesium stents under Real-World scrutiny in major registry

NCT ID NCT04679740

Disease control Sponsor: Biotronik AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry is tracking over 1,100 people with coronary artery disease who receive resorbable magnesium scaffolds—stents that slowly dissolve over time. The goal is to see how well these devices work in everyday medical practice, focusing on safety and whether they keep arteries open after one year. Participants are treated according to standard guidelines, with no extra restrictions beyond the device's instructions for use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magmaris and Freesolve resorbable magnesium scaffolds (drug-eluting devices)
What this could lead to
If successful, this registry could confirm that resorbable magnesium scaffolds are a safe and effective option for opening blocked heart arteries, potentially reducing the need for permanent metal stents.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove the scaffolds are better than existing treatments. Risks include scaffold failure, blood clots, or the need for repeat procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,106 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with symptomatic coronary artery disease needing the treatment of de novo native coronary artery lesions

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * According to the IFU Exclusion Criteria: * According to the IFU

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ w Lublinie

    RECRUITING

    Lublin, Poland

  • Cairns Hospital

    COMPLETED

    Cairns, 4870, Australia

  • Centre Hospitalier Universitaire Vaudois

    RECRUITING

    Lausanne, 1005, Switzerland

  • Centro Cardiologico Monzino

    RECRUITING

    Milan, Lombardy, 20138, Italy

  • Daugavpils Regional Hospital

    COMPLETED

    Daugavpils, LV-5417, Latvia

  • Heart Center Segeberger Kliniken

    RECRUITING

    Bad Segeberg, 23795, Germany

  • Herz-und Gefäßzentrum Oberallgäu-Kempten

    COMPLETED

    Kempten, Germany

  • Klinikum Herford

    COMPLETED

    Herford, 32049, Germany

  • Klinikum Westfalen, Knappschaft KH

    COMPLETED

    Dortmund, 44309, Germany

  • Krankenhaus Buchholz

    COMPLETED

    Buchholz, 21244, Germany

  • Lindenhofspital

    RECRUITING

    Bern, 3001, Switzerland

  • SUSCCH Banska Bystrica

    COMPLETED

    Banská Bystrica, 974 01, Slovakia

  • Solothurner Spitäler AG

    RECRUITING

    Olten, 4600, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.